![[ICO]](/icons/blank.gif){kind=icon}
![[PARENTDIR]](/icons/back.gif){kind=icon}
![[ ]](/icons/layout.gif){kind=icon}
| Name | Last modified | Size | Description |
|---|---|---|---|---|
| Parent Directory | - | ||
| tivozanib.pdf | 2022-09-15 12:14 | 474K | |
| pertuzumab-trastuzumab.pdf | 2022-09-15 12:14 | 483K | |
| olaparib.pdf | 2022-09-15 12:14 | 418K | |
| osimertinib.pdf | 2022-09-15 12:14 | 325K | |
| ramucirumab.pdf | 2022-09-15 12:14 | 327K | |
| cabozantinib.pdf | 2022-09-15 12:14 | 416K | |
| everolimus.pdf | 2022-09-15 12:14 | 264K | |
| atezolizumab.pdf | 2022-09-15 12:14 | 557K | |
| avelumab.pdf | 2022-09-15 12:14 | 372K | |
| durere-cronica-cancer.pdf | 2022-12-01 19:38 | 358K | |
| interferon-alfa-2a.pdf | 2022-12-01 19:38 | 316K | |
| pemetrexed.pdf | 2022-12-01 19:38 | 347K | |
| sunitinib.pdf | 2022-12-01 19:38 | 349K | |
| goserelina.pdf | 2022-12-01 19:38 | 358K | |
| leuprorelina.pdf | 2022-12-01 19:38 | 384K | |
| sorafenib.pdf | 2022-12-01 19:38 | 362K | |
| cetuximab.pdf | 2022-12-01 19:38 | 359K | |
| trastuzumab-metastatic.pdf | 2022-12-01 19:38 | 320K | |
| pegfilgrastim.pdf | 2022-12-01 19:38 | 378K | |
| erlotinib.pdf | 2022-12-01 19:38 | 332K | |
| trastuzumab-non-metastatic.pdf | 2022-12-01 19:38 | 332K | |
| cyproteron.pdf | 2022-12-01 19:38 | 224K | |
| epoetine.pdf | 2022-12-01 19:38 | 339K | |
| imatinib.pdf | 2022-12-01 19:38 | 337K | |
| acid-zoledronic.pdf | 2022-12-01 19:38 | 270K | |
| bevacizumab.pdf | 2022-12-01 19:38 | 411K | |
| fulvestrant.pdf | 2022-12-01 19:38 | 341K | |
| abiraterona.pdf | 2022-12-01 19:38 | 355K | |
| apalutamida.pdf | 2022-12-01 19:38 | 536K | |
| enzalutamida.pdf | 2022-12-01 19:38 | 351K | |
| acid-ibandronic.pdf | 2022-12-01 19:38 | 278K | |
| aflibercept.pdf | 2022-12-01 19:38 | 331K | |
| irinotecan-onyvide.pdf | 2022-12-01 19:38 | 341K | |
| abemaciclib.pdf | 2022-12-01 19:38 | 344K | |
| ribociclib.pdf | 2022-12-01 19:38 | 330K | |
| alectinib.pdf | 2022-12-01 19:38 | 355K | |
| palbociclib.pdf | 2022-12-01 19:38 | 332K | |
| ceritinib.pdf | 2022-12-01 19:38 | 267K | |
| dabrafenib-trametinib.pdf | 2022-12-01 19:38 | 363K | |
| dabrafenib.pdf | 2022-12-01 19:38 | 341K | |
| regoafenib.pdf | 2022-12-01 19:39 | 362K | |
| axitinib.pdf | 2022-12-01 19:39 | 331K | |
| crizotinib.pdf | 2022-12-01 19:39 | 254K | |
| vemurafenib.pdf | 2022-12-01 19:39 | 368K | |
| afatinib.pdf | 2022-12-01 19:39 | 334K | |
| vandetanib.pdf | 2022-12-01 19:39 | 249K | |
| pazopanib.pdf | 2022-12-01 19:39 | 367K | |
| everolimus-afinitor.pdf | 2022-12-01 19:39 | 328K | |
| lapatinib.pdf | 2022-12-01 19:39 | 299K | |
| gefitinib.pdf | 2022-12-01 19:39 | 384K | |
| cemiplimab.pdf | 2022-12-01 19:39 | 581K | |
| durvalumab.pdf | 2022-12-01 19:39 | 600K | |
| pembrolizumab.pdf | 2022-12-01 19:39 | 653K | |
| nivolumab.pdf | 2022-12-01 19:39 | 611K | |
| trastuzumab-emtansina.pdf | 2022-12-01 19:39 | 333K | |
| pertuzuzumab.pdf | 2022-12-01 19:39 | 529K | |
| nivo-ipi.pdf | 2022-12-01 19:39 | 489K | |
| ipilimumab.pdf | 2022-12-01 19:39 | 327K | |
| trabectedina.pdf | 2022-12-01 19:39 | 336K | |
| cabazitaxel.pdf | 2022-12-01 19:39 | 338K | |
| lonsurf.pdf | 2022-12-01 19:39 | 344K | |
| acid-clodronic.pdf | 2022-12-01 19:39 | 272K | |
| tumori-neuroendocrine.pdf | 2022-12-01 19:39 | 370K | |
| TEV.pdf | 2022-12-01 19:39 | 352K | |
| antiemetice.pdf | 2022-12-01 19:39 | 388K | |
| panitumumab.pdf | 2023-02-10 09:22 | 332K | |